{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T05:41:29Z","timestamp":1737783689852,"version":"3.33.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacepopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACEP Open"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1002\/emp2.13333","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T05:38:52Z","timestamp":1731044332000},"page":"e13333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of factor Xa inhibitor\u2013related traumatic non\u2010intracranial bleeding events with andexanet alfa or four\u2010factor prothrombin complex concentrate in a US multicenter observational study"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2668-7168","authenticated-orcid":false,"given":"Paul P.","family":"Dobesh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig I.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Danese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Les\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond C.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onivefu","family":"Odelade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory J.","family":"Fermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10159","key":"10.1002\/emp2.13333_bb0010","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age\u2010sex\u2010specific mortality for 282 causes of death in 195 countries and territories, 1980\u20102017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"issue":"23","key":"10.1002\/emp2.13333_bb0015","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1182\/blood-2018-06-850396","article-title":"Reversing anti\u2013factor Xa agents and the unmet needs in trauma patients","volume":"132","author":"Hunt","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1002\/emp2.13333_bb0020","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/SLA.0000000000000837","article-title":"Detailed description of all deaths in both the shock and traumatic brain injury hypertonic saline trials of the Resuscitation Outcomes Consortium","volume":"261","author":"Tisherman","year":"2015","journal-title":"Ann Surg"},{"issue":"5","key":"10.1002\/emp2.13333_bb0025","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Tomaselli","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1002\/emp2.13333_bb0030","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.injury.2020.06.010","article-title":"The effect of preinjury anticoagulation on mortality in trauma patients: a systematic review and meta\u2010analysis","volume":"51","author":"Lee","year":"2020","journal-title":"Injury"},{"issue":"4","key":"10.1002\/emp2.13333_bb0035","first-page":"S67","article-title":"Exploring indications for the use of direct oral anticoagulants and the associated risks of major bleeding","volume":"23","author":"Milling","year":"2017","journal-title":"Am J Manag Care"},{"issue":"8","key":"10.1002\/emp2.13333_bb0040","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/rth2.12418","article-title":"Andexanet versus prothrombin complex concentrates: differences in reversal of factor Xa inhibitors in in vitro thrombin generation","volume":"4","author":"Lu","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"10.1002\/emp2.13333_bb0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.54916","article-title":"Prothrombin complex concentrate vs conservative management in ICH associated with direct oral anticoagulants","volume":"7","author":"Ip","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"14","key":"10.1002\/emp2.13333_bb0050","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1002\/emp2.13333_bb0055","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"Final study report of andexanet alfa for major bleeding with factor Xa inhibitors","volume":"147","author":"Milling","year":"2023","journal-title":"Circulation"},{"issue":"19","key":"10.1002\/emp2.13333_bb0060","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for factor Xa inhibitor\u2010related acute intracerebral hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1002\/emp2.13333_bb0065","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13054-023-04327-7","article-title":"The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition","volume":"27","author":"Rossaint","year":"2023","journal-title":"Crit Care"},{"issue":"2","key":"10.1002\/emp2.13333_bb0070","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/TA.0000000000002979","article-title":"Early anticoagulant reversal after trauma: a Western Trauma Association critical decisions algorithm","volume":"90","author":"Peck","year":"2021","journal-title":"J Trauma Acute Care Surg"},{"issue":"6","key":"10.1002\/emp2.13333_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102192","article-title":"Lower mortality with andexanet alfa vs 4\u2010factor prothrombin complex concentrate for factor Xa inhibitor\u2010related major bleeding in a U.S. hospital\u2010based observational study","volume":"7","author":"Dobesh","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"10.1002\/emp2.13333_bb0080","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.annemergmed.2014.03.025","article-title":"Looking through the retrospectoscope: reducing bias in emergency medicine chart review studies","volume":"64","author":"Kaji","year":"2014","journal-title":"Ann Emerg Med"},{"issue":"5","key":"10.1002\/emp2.13333_bb0085","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.amjsurg.2022.06.019","article-title":"Nonoperative management of blunt abdominal solid organ injury: are we paying enough attention to patients on preinjury anticoagulation?","volume":"224","author":"Reina","year":"2022","journal-title":"Am J Surg"},{"issue":"2","key":"10.1002\/emp2.13333_bb0090","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjsurg.2020.12.034","article-title":"The AAST prospective observational multicenter study of the initial experience with reversal of direct oral anticoagulants in trauma patients","volume":"222","author":"Emigh","year":"2021","journal-title":"Am J Surg"},{"issue":"4","key":"10.1002\/emp2.13333_bb0095","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/jamaneurol.2024.0221","article-title":"Time to anticoagulation reversal and outcomes after intracerebral hemorrhage","volume":"81","author":"Sheth","year":"2024","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1002\/emp2.13333_bb0100","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/TA.0000000000001414","article-title":"Novel oral anticoagulants and trauma: the results of a prospective American Association for the Surgery of Trauma Multi\u2010Institutional Trial","volume":"82","author":"Kobayashi","year":"2017","journal-title":"J Trauma Acute Care Surg"},{"issue":"1","key":"10.1002\/emp2.13333_bb0105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.injury.2016.08.016","article-title":"Direct oral anticoagulants compared with warfarin in patients with severe blunt trauma","volume":"48","author":"Feeney","year":"2017","journal-title":"Injury"},{"issue":"1","key":"10.1002\/emp2.13333_bb0110","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00068-020-01429-7","article-title":"Mortality in relation to presence and type of oral antithrombotic agent among adult trauma patients: a single\u2010center retrospective cohort study","volume":"48","author":"Yuval","year":"2022","journal-title":"Eur J Trauma Emerg Surg"},{"issue":"4","key":"10.1002\/emp2.13333_bb0115","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.surg.2019.04.039","article-title":"Association of mortality among trauma patients taking preinjury direct oral anticoagulants versus vitamin K antagonists","volume":"166","author":"LaDuke","year":"2019","journal-title":"Surgery"},{"issue":"1","key":"10.1002\/emp2.13333_bb0120","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94675-7","article-title":"Impact of anticoagulation and antiplatelet drugs on surgery rates and mortality in trauma patients","volume":"11","author":"Blasius","year":"2021","journal-title":"Sci Rep"},{"issue":"3","key":"10.1002\/emp2.13333_bb0125","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jemermed.2016.05.005","article-title":"The severity of bleeding and mortality in trauma patients taking dabigatran","volume":"51","author":"Dezman","year":"2016","journal-title":"J Emerg Med"},{"issue":"2","key":"10.1002\/emp2.13333_bb0130","article-title":"Thirty\u2010day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life\u2010threatening direct oral anticoagulant\u2010related bleeding","volume":"3","author":"Cohen","year":"2022","journal-title":"J Am Coll Emerg Physicians Open"},{"issue":"1","key":"10.1002\/emp2.13333_bb0135","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13054-022-04043-8","article-title":"Andexanet alfa versus four\u2010factor prothrombin complex concentrate for the reversal of apixaban\u2010 or rivaroxaban\u2010associated intracranial hemorrhage: a propensity score\u2010overlap weighted analysis","volume":"26","author":"Costa","year":"2022","journal-title":"Crit Care"}],"container-title":["JACEP Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2688115224015029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2688115224015029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/emp2.13333","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T02:21:53Z","timestamp":1737771713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2688115224015029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2688115224015029"],"URL":"https:\/\/doi.org\/10.1002\/emp2.13333","relation":{},"ISSN":["2688-1152"],"issn-type":[{"type":"print","value":"2688-1152"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of factor Xa inhibitor\u2013related traumatic non\u2010intracranial bleeding events with andexanet alfa or four\u2010factor prothrombin complex concentrate in a US multicenter observational study","name":"articletitle","label":"Article Title"},{"value":"JACEP Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/emp2.13333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 THE AUTHORS. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"e13333"}}